Ox­ford and No­vavax tout 75%+ ef­fi­ca­cy for malar­ia vac­cine, best­ing Glax­o­SmithK­line in long hunt to in­oc­u­late against the dead­ly par­a­site

No­vavax and Ox­ford’s Jen­ner In­sti­tute have spent the last 16 months mak­ing head­lines for their Covid-19 vac­cines. But, qui­et­ly, the two groups have al­so spent that time work­ing on an in­oc­u­la­tion for a dif­fer­ent dead­ly pathogen: malar­ia.

That ef­fort has now brought its first ma­jor re­sult. In The Lancet Fri­day, in­ves­ti­ga­tors re­port­ed that their ex­per­i­men­tal malar­ia vac­cine was 77% ef­fec­tive at pre­vent­ing malar­ia in a tri­al of 450 chil­dren in Burk­i­na Fa­so.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER